Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Total Debt (2020 - 2022)

Anika Therapeutics (ANIK) has disclosed Total Debt for 7 consecutive years, with $4.3 million as the latest value for Q2 2022.

  • On a quarterly basis, Total Debt fell 74.42% to $4.3 million in Q2 2022 year-over-year; TTM through Jun 2022 was $4.3 million, a 74.42% decrease, with the full-year FY2021 number at $4.3 million, down 67.04% from a year prior.
  • Total Debt was $4.3 million for Q2 2022 at Anika Therapeutics, roughly flat from $4.3 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $50.0 million in Q2 2020 to a low of $4.3 million in Q3 2021.
  • A 3-year average of $16.3 million and a median of $13.1 million in 2020 define the central range for Total Debt.
  • Biggest YoY gain for Total Debt was 66.26% in 2021; the steepest drop was 82.8% in 2021.
  • Anika Therapeutics' Total Debt stood at $13.1 million in 2020, then tumbled by 67.04% to $4.3 million in 2021, then changed by 0.0% to $4.3 million in 2022.
  • Per Business Quant, the three most recent readings for ANIK's Total Debt are $4.3 million (Q2 2022), $4.3 million (Q1 2022), and $4.3 million (Q4 2021).